Volume No. :   9

Issue No. :  2

Year :  2019

ISSN Print :  2231-5705

ISSN Online :  2231-5713


Allready Registrered
Click to Login

Formulation Development and Characterisation of Repaglinide Buccal Tablets

Address:   Kuldeep P. Waidya1*, S. Ramya Sri2, T. Janaki3
1,3Department of Industrial Pharmacy, Nalanda College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana
2 Research scholar, Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, Telangana
*Corresponding Author
DOI No: 10.5958/2231-5713.2019.00014.X

The objective of this study was to develop effective buccal tablets of Repaglinide. Tablets of Repaglinide were prepared by direct compression method using bioadhesive polymers like Chitosan, Guargum, Xanthan gum. Buccal tablets were prepared by taking polymers in different ratios. Buccal tablets were evaluated by different parameters such as thickness, hardness, weight uniformity, content uniformity, surface pH, in-vitro drug release, ex vivo drug permeation, in vivo mucoadhesive performance studies. In vitro assembly was used to measure the bioadhesive strength of tablets with fresh porcine buccal mucosa as model tissue. The tablets were evaluated for in vitro release in pH 6.8 phosphate buffer for 8 hr in standard dissolution apparatus. In order to determine the mode of release, the data was subjected to Zero order, first order, Higuchi, Korsmeyer and Peppas diffusion model. The formulation F3 showed maximum drug release (89.06%) in 8 hrs. The optimised formulation F3 showed a surface pH of 6.18. This formulation was following Zero order mechanism with regression value of 0.981. FT-IR studies revealed the absence of any chemical interaction between drug and polymers used. Repaglinide buccal tablets for buccal delivery could be prepared with required in-vitro release properties.
Repaglinide, Buccal tablets, Chitosan, Guargum, Xanthan gum, in-vitro drug release.
Kuldeep P. Waidya, S. Ramya Sri, T. Janaki. Formulation Development and Characterisation of Repaglinide Buccal Tablets. Asian J. Pharm. Tech. 2019; 9(2):79-88.
[View HTML]     

Visitor's No. :   219694